| Product Code: ETC9517126 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Suriname Neurodegenerative Disease Treatment Market Overview |
3.1 Suriname Country Macro Economic Indicators |
3.2 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Suriname Neurodegenerative Disease Treatment Market - Industry Life Cycle |
3.4 Suriname Neurodegenerative Disease Treatment Market - Porter's Five Forces |
3.5 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Drug Type:, 2021 & 2031F |
3.7 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Route of Administration:, 2021 & 2031F |
3.8 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Distribution Channel:, 2021 & 2031F |
4 Suriname Neurodegenerative Disease Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurodegenerative diseases in Suriname |
4.2.2 Growing awareness about treatment options and healthcare services |
4.2.3 Advancements in medical research and technology for neurodegenerative disease treatment |
4.3 Market Restraints |
4.3.1 Limited access to specialized healthcare services in remote areas of Suriname |
4.3.2 High cost associated with neurodegenerative disease treatments |
4.3.3 Lack of skilled healthcare professionals and infrastructure for specialized care |
5 Suriname Neurodegenerative Disease Treatment Market Trends |
6 Suriname Neurodegenerative Disease Treatment Market, By Types |
6.1 Suriname Neurodegenerative Disease Treatment Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.1.4 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.1.5 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.1.6 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Spinal Muscular Atrophy (SMA), 2021- 2031F |
6.1.7 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Huntingtons Disease, 2021- 2031F |
6.1.8 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Suriname Neurodegenerative Disease Treatment Market, By Drug Type: |
6.2.1 Overview and Analysis |
6.2.2 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By N-methyl-D-aspartate Receptor Antagonists, 2021- 2031F |
6.2.3 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Selective Serotonin Reuptake Inhibitors, 2021- 2031F |
6.2.4 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Dopamine Inhibitors, 2021- 2031F |
6.2.5 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Suriname Neurodegenerative Disease Treatment Market, By Route of Administration: |
6.3.1 Overview and Analysis |
6.3.2 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.4 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Suriname Neurodegenerative Disease Treatment Market, By Distribution Channel: |
6.4.1 Overview and Analysis |
6.4.2 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 Suriname Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Suriname Neurodegenerative Disease Treatment Market Import-Export Trade Statistics |
7.1 Suriname Neurodegenerative Disease Treatment Market Export to Major Countries |
7.2 Suriname Neurodegenerative Disease Treatment Market Imports from Major Countries |
8 Suriname Neurodegenerative Disease Treatment Market Key Performance Indicators |
8.1 Average waiting time for neurodegenerative disease treatments |
8.2 Number of healthcare facilities offering specialized care for neurodegenerative diseases |
8.3 Patient satisfaction with the quality of neurodegenerative disease treatment services |
8.4 Percentage of the population receiving regular screenings for early detection of neurodegenerative diseases |
8.5 Number of clinical trials and research studies focused on neurodegenerative disease treatments in Suriname |
9 Suriname Neurodegenerative Disease Treatment Market - Opportunity Assessment |
9.1 Suriname Neurodegenerative Disease Treatment Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Suriname Neurodegenerative Disease Treatment Market Opportunity Assessment, By Drug Type:, 2021 & 2031F |
9.3 Suriname Neurodegenerative Disease Treatment Market Opportunity Assessment, By Route of Administration:, 2021 & 2031F |
9.4 Suriname Neurodegenerative Disease Treatment Market Opportunity Assessment, By Distribution Channel:, 2021 & 2031F |
10 Suriname Neurodegenerative Disease Treatment Market - Competitive Landscape |
10.1 Suriname Neurodegenerative Disease Treatment Market Revenue Share, By Companies, 2024 |
10.2 Suriname Neurodegenerative Disease Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here